US 11,939,354 B1
Fusion peptide inhibitors of human coronavirus 229E
Mahmoud Kandeel, Al-Ahsa (SA)
Assigned to KING FAISAL UNIVERSITY, Al-Ahsa (SA)
Filed by KING FAISAL UNIVERSITY, Al-Ahsa (SA)
Filed on Sep. 25, 2023, as Appl. No. 18/372,623.
Application 18/372,623 is a division of application No. 18/198,100, filed on May 16, 2023.
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/68 (2006.01); A61P 31/14 (2006.01); C07K 14/00 (2006.01); C07K 14/085 (2006.01)
CPC C07K 14/001 (2013.01) [A61P 31/14 (2018.01); C07K 2319/00 (2013.01)] 6 Claims
 
1. A method for conducting a human coronavirus 229E inhibition assay comprising:
(a) providing a HCoV-229E peptide inhibitor;
(b) providing a test inhibitor;
(c) assaying the HCoV-229E peptide inhibitor to obtain results for the HCoV-229E peptide inhibitor;
(d) assaying the test inhibitor to obtain results for the test inhibitor; and
(e) comparing the results for the HCoV-229 peptide inhibitor to the results for the test inhibitor to determine whether the test inhibitor inhibits HCoV-229 fusion;
wherein the HCoV-229E peptide inhibitor is selected from the group consisting of a peptide consisting of the amino acid sequence of SEQ ID NO: 2, a peptide consisting of the amino acid sequence of SEQ ID NO: 3, and a peptide consisting of the amino acid sequence of SEQ ID NO: 2 and the amino acid sequence of SEQ ID NO: 3, and a combination thereof.